Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine

Single-group, open-label pilot enrolling nine participants with treatment-resistant major depressive disorder to identify predictors of response to intranasal ketamine using MRI and blood biomarkers.

Participants undergo blood sampling and magnetic resonance imaging before and after intranasal ketamine administration (40 mg via mucosal atomization) and receive a subsequent second intranasal treatment; outcomes focus on biomarker change associated with clinical response.